Bio-techne Share Price (NASDAQ: TECH)

$57.1

▲

3.1

(5.74%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Bio-techne Stock chart to analyse performance

Bio-techne stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$54.98
Today's High:$57.38
$57.10
3.71%
Downside
Day's Volatility :4.18%
Upside
0.49%
52 Weeks Low:$46.01
52 Weeks High:$80.95
$57.10
19.42%
Downside
52 Weeks Volatility :43.16%
Upside
29.46%

Bio-techne Stock Returns

Period	Bio-techne Corp.	Sector (Health Care)	Index (Russel 2000)
3 Months	17.27%	6.0%	0.0%
6 Months	-12.9%	-6.4%	0.0%
1 Year	-19.96%	-11.1%	0.0%
3 Years	-36.31%	6.7%	-8.6%

Bio-techne Corp. Key Stats

Check Bio-techne key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$54.0
Open	$54.98
Today's High	$57.38
Today's Low	$54.98
Market Capitalization	$8.5B
Today's Volume	$1.4M
52 Week High	$80.9499
52 Week Low	$46.01
Revenue TTM	$1.2B
EBITDA	$233.0M
Earnings Per Share (EPS)	$0.46
PE Ratio	117.39
Dividend Yield	0.59%
Profit Margin	6.02%
Quarterly Earnings Growth YOY	-0.55%
Return On Equity TTM	3.68%

Stock Returns calculator for Bio-techne Stock including INR - Dollar returns

The Bio-techne stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Bio-techne investment value today

Current value as on today

₹84,355

Returns

₹15,645

(-15.64%)

Returns from Bio-techne Stock

₹19,961 (-19.96%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Bio-techne Stock

46%

Period: Jul 24, 2025 to Aug 23, 2025. Change in 30 Days versus previous period

Search interest for Bio-techne Stock from India on INDmoney has increased by 46% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Bio-techne Stock

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	1267	-3.21	0.02%

Global Institutional Holdings in Bio-techne Corp.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
11.76%
BlackRock Inc
8.77%
T. Rowe Price Associates, Inc.
5.64%
State Street Corp
4.17%
Morgan Stanley - Brokerage Accounts
3.65%
Select Equity Group LP
3.42%

Analyst Recommendation on Bio-techne Stock

Rating

Trend

Buy

84%Buy

15%Hold

0%Sell

Based on 19 Wall street analysts offering stock ratings for Bio-techne(by analysts ranked 0 to 5 stars)

Bio-techne Share Price Target

What analysts predicted

Upside of 14.37%

Target:

$65.31

Current:

$57.10

Bio-techne share price target is $65.31, a slight Upside of 14.37% compared to current price of $57.10 as per analysts' prediction.

Bio-techne Stock Insights

Price Movement
In the last 7 days, TECH stock has moved up by 6.5%
Increasing Revenue
Revenue is up for the last 3 quarters, 289.45M → 316.18M (in $), with an average increase of 4.3% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 34.89M → 22.58M (in $), with an average decrease of 35.3% per quarter
TECH vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.6% return, outperforming this stock by 87.6%
TECH vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 105.6% return, outperforming this stock by 139.8%
Price to Sales
ForTECH every $1 of sales, investors are willing to pay $7.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Bio-techne Corp. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$714.0M	↑ 11.04%
Net Income	$96.1M	↓ 23.36%
Net Profit Margin	13.46%	↓ 6.03%

	FY20	Y/Y Change
Revenue	$738.7M	↑ 3.46%
Net Income	$229.3M	↑ 138.67%
Net Profit Margin	31.04%	↑ 17.58%

	FY21	Y/Y Change
Revenue	$931.0M	↑ 26.04%
Net Income	$140.4M	↓ 38.76%
Net Profit Margin	15.08%	↓ 15.96%

	FY22	Y/Y Change
Revenue	$1.1B	↑ 18.75%
Net Income	$272.1M	↑ 93.75%
Net Profit Margin	24.61%	↑ 9.53%

	FY23	Y/Y Change
Revenue	$1.1B	↑ 2.81%
Net Income	$285.3M	↑ 4.86%
Net Profit Margin	25.1%	↑ 0.49%

	FY24	Y/Y Change
Revenue	$1.2B	↑ 1.97%
Net Income	$168.1M	↓ 41.07%
Net Profit Margin	14.5%	↓ 10.6%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Revenue	$272.6M	↓ 1.57%
Net Income	$27.5M	↓ 46.14%
Net Profit Margin	10.08%	↓ 8.33%

	Q1 FY24	Q/Q Change
Revenue	$303.4M	↑ 11.31%
Net Income	$49.1M	↑ 78.62%
Net Profit Margin	16.17%	↑ 6.09%

	Q2 FY24	Q/Q Change
Revenue	$306.1M	↑ 0.88%
Net Income	$40.6M	↓ 17.27%
Net Profit Margin	13.26%	↓ 2.91%

	Q3 FY24	Q/Q Change
Revenue	$289.5M	↓ 5.44%
Net Income	$33.6M	↓ 17.22%
Net Profit Margin	11.61%	↓ 1.65%

	Q4 FY24	Q/Q Change
Revenue	$297.0M	↑ 2.62%
Net Income	$34.9M	↑ 3.84%
Net Profit Margin	11.75%	↑ 0.14%

	Q1 FY25	Q/Q Change
Revenue	$316.2M	↑ 6.45%
Net Income	$22.6M	↓ 35.26%
Net Profit Margin	7.14%	↓ 4.61%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$473.5M	↑ 9.57%

	FY20	Y/Y Change
Profit	$483.2M	↑ 2.05%

	FY21	Y/Y Change
Profit	$632.9M	↑ 30.97%

	FY22	Y/Y Change
Profit	$756.5M	↑ 19.54%

	FY23	Y/Y Change
Profit	$769.8M	↑ 1.76%

	FY24	Y/Y Change
Profit	$769.7M	↓ 0.01%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Profit	$176.6M	↓ 4.65%

	Q1 FY24	Q/Q Change
Profit	$205.2M	↑ 16.23%

	Q2 FY24	Q/Q Change
Profit	$204.9M	↓ 0.18%

	Q3 FY24	Q/Q Change
Profit	$183.0M	↓ 10.67%

	Q4 FY24	Q/Q Change
Profit	$193.9M	↑ 5.94%

	Q1 FY25	Q/Q Change
Profit	$214.6M	↑ 10.66%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$181.6M	↑ 6.6%
Investing Cash Flow	$-336.8M	↑ 770.01%
Financing Cash Flow	$134.4M	↓ 235.48%

	FY20	Y/Y Change
Operating Cash Flow	$205.2M	↑ 12.99%
Investing Cash Flow	$27.1M	↓ 108.04%
Financing Cash Flow	$-183.8M	↓ 236.77%

	FY21	Y/Y Change
Operating Cash Flow	$352.2M	↑ 71.61%
Investing Cash Flow	$-243.5M	↓ 998.75%
Financing Cash Flow	$-62.6M	↓ 65.97%

	FY22	Y/Y Change
Operating Cash Flow	$325.3M	↓ 7.64%
Investing Cash Flow	$-96.9M	↓ 60.23%
Financing Cash Flow	$-242.9M	↑ 288.25%

	FY23	Y/Y Change
Operating Cash Flow	$254.4M	↓ 21.79%
Investing Cash Flow	$-265.6M	↑ 174.29%
Financing Cash Flow	$22.6M	↓ 109.31%

	FY24	Y/Y Change
Operating Cash Flow	$299.0M	↑ 17.53%
Investing Cash Flow	$-203.0M	↓ 23.57%
Financing Cash Flow	$-122.4M	↓ 641.2%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Operating Cash Flow	$83.1M	↑ 39.97%
Investing Cash Flow	$-23.7M	↓ 84.64%
Financing Cash Flow	$-81.4M	↓ 213.83%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$81.0M	↓ 2.56%
Investing Cash Flow	$-16.4M	↓ 30.54%
Financing Cash Flow	$-52.4M	↓ 35.61%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$75.5M	↓ 6.78%
Investing Cash Flow	$-8.8M	↓ 46.43%
Financing Cash Flow	$-60.1M	↑ 14.65%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$63.9M	↓ 15.37%
Investing Cash Flow	$-21.7M	↑ 146.19%
Financing Cash Flow	$-11.6M	↓ 80.75%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$84.3M	↑ 32.02%
Investing Cash Flow	$-5.0M	↓ 76.79%
Financing Cash Flow	$-83.8M	↑ 624.54%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$41.1M	↓ 51.25%
Investing Cash Flow	$-8.9M	↑ 76.33%
Financing Cash Flow	$-68.0M	↓ 18.84%

Bio-techne Technicals Summary

Sell

Neutral

Buy

Bio-techne is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Bio-techne Corp. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bio-techne Corp.	-2.86%	-12.9%	-19.96%	-36.31%	-8.97%
Regeneron Pharmaceuticals, Inc.	4.66%	-17.37%	-50.86%	-2.39%	-3.46%
Beone Medicines Ltd	7.62%	21.35%	57.45%	78.28%	25.05%
Vertex Pharmaceuticals Incorporated	-15.87%	-17.97%	-18.14%	35.67%	45.07%
Alnylam Pharmaceuticals, Inc.	38.16%	82.49%	68.79%	112.36%	238.79%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bio-techne Corp.	117.39	117.39	0.72	1.91	0.04	0.03	0.01	12.39
Regeneron Pharmaceuticals, Inc.	15.08	15.08	1.23	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	28.25	28.25	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bio-techne Corp.	Buy	$8.5B	-8.97%	117.39	6.02%
Regeneron Pharmaceuticals, Inc.	Buy	$63.4B	-3.46%	15.08	31.37%
Beone Medicines Ltd	NA	$38.2B	25.05%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$101.9B	45.07%	28.25	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$60.1B	238.79%	NA	-12.96%

Bio-techne Dividend announcements

Bio-techne Dividends September, 2025
In the quarter ending September,2025. Bio-techne has declared dividend of $0.08

About Bio-techne Corp.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Organization	Bio-techne
Employees	3100
CEO	Mr. Kim Kelderman
Industry	Health Technology

Key Management of Bio-techne Corp.

Name	Title
Mr. Kim Kelderman	CEO, President & Director
Mr. James T. Hippel CPA	Executive VP of Finance & CFO
Mr. Shane Bohnen	Senior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer
Mr. William A. Geist	President of Protein Sciences Segment
Dr. Matthew F. McManus M.D., MBA, Ph.D.	President of Diagnostics & Genomics
Dr. Gary J. Latham Ph.D.	VP & CTO
Mr. David Clair C.F.A.	VP of Investor Relations & Corporate Development
Mr. Gerry Andros	Vice President of Sales and Marketing
Mr. Martin Wirtz	Senior Vice President of Strategy & Corporate Development
Ms. Cheryl Bethune	Senior VP & Chief Human Resources Officer

Important FAQs about investing in TECH Stock from India :

What is Bio-techne share price today?

Bio-techne share price today is $57.10 as on August 23, 2025 at 1:29 AM IST at the close of the market. Bio-techne share today touched a day high of $57.38 and a low of $54.98.

What is the 52 week high and 52 week low for Bio-techne share?

Bio-techne share touched a 52 week high of $80.95 and a 52 week low of $46.01. Bio-techne stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $57.10, lower by 29.46% versus the 52 week high.

How to invest in Bio-techne Stock (TECH) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Bio-techne on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Bio-techne Shares that will get you 0.0263 shares as per Bio-techne share price of $57.10 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Bio-techne Stock (TECH) from India?

Indian investors can start investing in Bio-techne (TECH) shares with as little as ₹87.521 or $1 (as of August 24, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Bio-techne stock (as per the Rupee-Dollar exchange rate as on August 24, 2025). Based on Bio-techne share’s latest price of $57.10 as on August 23, 2025 at 1:29 AM IST, you will get 0.1751 shares of Bio-techne. Learn more about fractional shares .

What are the returns that Bio-techne has given to Indian investors in the last 5 years?

Bio-techne stock has given -8.97% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?